Physician
Center for Pain Management, LLC
Center for Pain Management, LLC was paid $15K by Medicaid between Jan 2018 and Nov 2019, across 4 billing codes. Its largest line is 80307, Drug test(s), presumptive, any number of drug classes; immunoassay — 42% of everything it billed.
33Billing provider infoCENTER FOR PAIN MANAGEMENT, LLC
COLUMBIA, MD 21045
COLUMBIA, MD 21045
33aNPI1689004277assigned 11/18/2013
33bProvider typeInterventional Pain Medicine Physician
28Total paid$15K
24GClaims4,254
24DCodes billed4
24AFirst – last monthJan 2018 – Nov 2019
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Maryland
Rank by total paid#7 of 8
Median peer was paid$148K
This provider vs. median0.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official TINCH, SHANEKA controls 16+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 2,443 | $10K | |
| 2019 | 1,811 | $5K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 42% | 2,249 | 1,923 | $6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 35% | 904 | 761 | $5K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 13% | 960 | 832 | $2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 11% | 141 | 135 | $2K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialTINCH, SHANEKA (RCM MANAGER)
| Provider | Location | Paid |
|---|---|---|
| Center for Pain Management, LLC | Hagerstown, MD | $18.80M |
| Interventional Pain Center PLLC | Fayetteville, NC | $6.14M |
| Physical Medicine Associates, LTD | Mc Lean, VA | $1.79M |
| Asc Development Company, LLC | Hagerstown, MD | $113K |
| Asc Development Company, LLC | Frederick, MD | $42K |
| Asc Development Company, LLC | Germantown, MD | $31K |
| Florida Pain and Rehabilitation Associates INC | Delray Beach, FL | $25K |
| Asc Development Company, LLC | Pikesville, MD | $24K |
| Asc Development Company, LLC | Glen Burnie, MD | $24K |
| Asc Development Company LLC | White Plains, MD | $14K |
| Asc Development Company, LLC | Bel Air, MD | $7K |
| NSPC Surgery Center of Maryland LLC | Oxon Hill, MD | $6K |
| National Surgical Centers of America LLC | Winter Park, FL | $2K |
| Florida Pain and Rehabilitation Associates INC | Delray Beach, FL | $377.09 |
| Pain Consultants Asc LLC | Pascagoula, MS | $0.00 |
| Physical Medicine Associates LTD | Oxon Hill, MD | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.